(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Menu Back to Committee

Meet the Program Commitee for 2021!

Program Committee

  • Matt Baldwin, MS
    Matt Baldwin, MS • Biomedical Data Stewardship Senior Manager
    Amgen, United States
  • Amy Bertha
    Amy Bertha • Executive Director, Regulatory Policy and Innovation
    Bayer, United States
  • Poonam Bordoloi, PharmD
    Poonam Bordoloi, PharmD • Executive Director, Head of Global Medical Affairs Capabilities
    Organon & Co., United States
  • David Bowers, PharmD
    David Bowers, PharmD • Senior Director, Operations
    PPD, United States
  • Kristina Bowyer
    Kristina Bowyer • Vice President, Patient Advocacy & Engagement
    Ionis Pharmaceuticals, Inc., United States
  • Philip (P.J.) Brooks, PhD
    Philip (P.J.) Brooks, PhD • Deputy Director, Division of Rare Diseases Research Innovation
    National Center for Advancing Translational Sciences (NCATS), NIH, United States
  • Bill Byrom, PhD
    Bill Byrom, PhD • Vice President, Product Intelligence and Positioning; Principal, eCOA Science
    Signant Health , United Kingdom
  • Meghana Chalasani, MHA
    Meghana Chalasani, MHA • Lead, Advisory Committees, Office of New Drugs, CDER
    FDA, United States
  • Andrew Chang, PhD
    Andrew Chang, PhD • Vice President, Quality and Regulatory Compliance
    Novo Nordisk, Inc., United States
  • Karla Childers, MS
    Karla Childers, MS • Head, Bioethics-Based Science and Technology Policy
    Johnson & Johnson, United States
  • Leah Christl, PhD
    Leah Christl, PhD • Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
    Amgen, United States
  • Freda Cooner, PhD
    Freda Cooner, PhD • Senior Director - Statistics
    Eli Lilly and Company, United States
  • Stephanie Y. Crawford, PhD, MPH, MS
    Stephanie Y. Crawford, PhD, MPH, MS • Professor, Pharmacy Systems, Outcomes and Policy
    University of Illinois at Chicago, United States
  • Julie Dietrich, MS
    Julie Dietrich, MS • Vice President, Clinical Development
    GENFIT, United States
  • Sonya Eremenco, MA
    Sonya Eremenco, MA • Executive Director, PRO Consortium
    Critical Path Institute, United States
  • Jennifer Farmer, MS
    Jennifer Farmer, MS • Chief Executive Officer
    Friedreich's Ataxia Research Alliance (FARA), United States
  • Ron Fitzmartin, PhD, MBA
    Ron Fitzmartin, PhD, MBA • Senior Informatics Advisor, Office of Regulatory Operations, CBER
    FDA, United States
  • David Fryrear, MS
    David Fryrear, MS • Executive Vice President and Head of Quality Assurance
    Astellas, United States
  • M. Scott Furness, PhD
    M. Scott Furness, PhD • Deputy Director, Office of New Drug Products, OPQ, CDER
    FDA, United States
  • Alicia Gilsenan, PhD, MS, RPh, FISPE
    Alicia Gilsenan, PhD, MS, RPh, FISPE • Vice President, Epidemiology
    RTI Health Solutions, United States
  • Renmeet Grewal, PharmD, MS
    Renmeet Grewal, PharmD, MS • Division Director, Office of Regulatory Operations (DRO-II), OND, CDER
    FDA, United States
  • Sabine Haubenreisser, PhD, MSc
    Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
    European Medicines Agency, Netherlands
  • Alan Hochberg
    Alan Hochberg • Principal Scientific Enablement Director, Scientific Enablement and Processes
    Genentech, A Member of the Roche Group, United States
  • Michelle Hoiseth
    Michelle Hoiseth • General Manager, Project-Based Services
    Cytel, United States
  • Kenneth Hu, PharmD, MBA
    Kenneth Hu, PharmD, MBA • Senior Manager (US Reg Lead), Global Regulatory Strategy & Policy, Oncology
    Bristol Myers Squibb, United States
  • Jeremy Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS • Vice President and Head, Safety Evidence and Sciences
    Bristol-Myers Squibb Company, United States
  • Darryl L'Heureux, PhD, MPharm, MSc
    Darryl L'Heureux, PhD, MPharm, MSc • Director, Clinical Science, Medical Writing, and Publications
    Ambrx, Inc, United States
  • Erik Laughner
    Erik Laughner • Project Manager, Business Operations Staff, OD, CBER
    FDA, United States
  • Cathryn C Lee, MSN
    Cathryn C Lee, MSN • Director, Office of Program Operations, PDIMS, OND, CDER
    FDA, United States
  • Rebecca Lipsitz, PhD
    Rebecca Lipsitz, PhD • Senior Director, TA Regulatory Intelligence and Portfolio Policy, Late R&I RA
    AstraZeneca, United States
  • Sheila Mahoney Jewels, MBA
    Sheila Mahoney Jewels, MBA • Drug Development Multi-Functionalist
    LifeSciHub , United States
  • Ingrid Markovic, PhD
    Ingrid Markovic, PhD • Senior Science Advisor for CMC, Office of the Center Director, CBER
    FDA, United States
  • Christopher Marrone, PharmD, RPh
    Christopher Marrone, PharmD, RPh • Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)
    Eli Lilly and Company, United States
  • Chris Matheus, MBA
    Chris Matheus, MBA • Chief Commercial and Networking Officer
    Global Life Sciences Alliance (GLSA), United States
  • K. Kimberly McCleary
    K. Kimberly McCleary • Founder and Chief Executive Officer
    The Kith Collective, LLC, United States
  • Lindsay McNair, MD, MPH, MS
    Lindsay McNair, MD, MPH, MS • Principal Consultant
    Equipoise Consulting, United States
  • Ann Meeker-O'Connell, MS
    Ann Meeker-O'Connell, MS • Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC
    FDA, United States
  • Christine Moore, PhD
    Christine Moore, PhD • Executive Director, Global External Advocacy and Standards
    Organon & Co., United States
  • Jean M. Mulinde, MD
    Jean M. Mulinde, MD • Associate Director, Division of Clinical Compliance Evaluation, OSI
    FDA, United States
  • Erin Mulrooney, MSc, PMP
    Erin Mulrooney, MSc, PMP • Director, Discovery Project and Portfolio Management
    Merck Sharp & Dohme LLC , United States
  • Nobumasa Nakashima
    Nobumasa Nakashima • Health Policy Director, National Healthcare Policy Secretariat
    Cabinet Office, Japan
  • Anita Nelsen
    Anita Nelsen • Executive Vice President, Translational Medicine
    Parexel, United States
  • David O Olaleye, PhD, MSc
    David O Olaleye, PhD, MSc • Senior Manager and Principal Research Statistician
    SAS Institute Inc., United States
  • Sissi Pham, PharmD
    Sissi Pham, PharmD • Chief Executive Officer
    AESARA, United States
  • Paul Phillips
    Paul Phillips • Director, Office of Program Operations, OND, CDER
    FDA, United States
  • Margaret Richards, PhD, MPH
    Margaret Richards, PhD, MPH • Executive Director, Solutions
    Panalgo, United States
  • Steven L. Roberds, PhD
    Steven L. Roberds, PhD • Chief Scientific Officer
    Tuberous Sclerosis Alliance, United States
  • Earl Seltzer, MBA
    Earl Seltzer, MBA • Senior Director, Partnerships and Innovation
    CTI, United States
  • Nancy Slater, MBA, PMP
    Nancy Slater, MBA, PMP • Senior Director, Portfolio Program Management Therapeutic Area Head
    AbbVie, Inc., United States
  • Nancy Pire Smerkanich, DrSc, MS
    Nancy Pire Smerkanich, DrSc, MS • Assistant Professor Regulatory & Quality Sciences
    University of Southern California School of Pharmacy, United States
  • Meredith Smith, PhD, MPA, FISPE
    Meredith Smith, PhD, MPA, FISPE • Senior Director, Implementation Science Pillar Lead
    Evidera, Inc, United States
  • Evelyn Soo, PhD, MS
    Evelyn Soo, PhD, MS • Director, Bureau of Gastroenterology, Infection and Viral Diseases, HPFB
    Health Canada, Canada
  • Mat Soukup, PhD
    Mat Soukup, PhD • Deputy Director, Division of Biometrics VII, OB, OTS CDER
    FDA, United States
  • Jeffrey N. Stuart, PhD
    Jeffrey N. Stuart, PhD • Associate Vice President, Global Regulatory Affairs
    Merck Sharp & Dohme LLC , United States
  • Ling Su, PhD
    Ling Su, PhD • Research Fellow
    Shenyang Pharmaceutical University, Yeehong Business School, China
  • Rachel Turow, JD, MPH
    Rachel Turow, JD, MPH • Managing Counsel, FDA Regulatory
    Walmart, Inc., United States
  • Daniel Urban, PhD
    Daniel Urban, PhD • Pharmacology/Toxicology Reviewer, OTAT, CBER
    FDA, United States
  • Paula Walker, MA
    Paula Walker, MA • Global Head of Risk Based Quality Management
    Roche Products Ltd., United Kingdom
  • Nancy Watanabe, MS, PMP
    Nancy Watanabe, MS, PMP • Independent Consultant
    Independent Consultant, United States
  • Keith Wenzel
    Keith Wenzel • Volunteer
    DIA Study Endpoints Community, United States
  • Judith Zander, MD
    Judith Zander, MD • Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER
    FDA , United States
Load More

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.